Heart failure detection startup Respirix has reported raising $1.3 million, according to a securities filing.
The San Francisco-based company has developed the handheld Cardiospire device to acquire data on cardiogenic oscillation from a patient’s airway to determine whether the patient is approaching congestive heart failure decompensation before experiencing symptoms.
Respirix, which was named one of MedTech Innovator accelerator companies for 2019, told that organization that it “has an opportunity to reduce more than $35 billion of annual costs associated with congestive heart failure hospitalizations in the U.S. alone, and estimated annual costs over $100 billion, with a solution that will be a win for patients, providers and payers.”